Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 372

Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

Dr Dominik Modest speaks to ecancer at ESMO 2019 in Barcelona about the VOLFI trial which compares a triplet chemotherapy with triplet chemotherapy plus the antibody panitumumab for colorectal cancer.

He outlines why this trial is important, having never established the specific role of this antibody before.

The primary endpoint was met, and there was a significant improvement between the arms.

Dr Modest rounds up by highlighting the importance of dosing, and some of the disparities still remaining around the treatment of this disease.

Related videos


no rating
Epidemiology of cancer in India

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation